Back to News
Market Impact: 0.2
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
Source: 247wallst.com
Capital Returns (Dividends / Buybacks)Healthcare & BiotechLegal & LitigationCompany Fundamentals
Johnson & Johnson recorded its 64th consecutive year of dividend growth. The article weighs that record against biosimilar threats, a MedTech slowdown, and ongoing talc litigation, questioning whether the dividend streak alone makes the stock a buy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
JNJ0.10
More News
- Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
- Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
- Jim Cramer's key to Wednesday's market — plus, relief for Intel after a concerning report
- High Court coal decision, Firmus IPO, diesel prices
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?